SAN DIEGO, Calif. — A new innovation in the detection of MSA pathology is here. Amprion, a global leader advancing diagnosis of neurodegenerative disorders through seed amplification testing, today announced the launch of SAAmplify®-αSYN Plus (CSF), the next generation of its alpha-synuclein seed amplification assay (SAA). The test launch marks...

PHILADELPHIA, PA — Imvax, Inc., a clinical-stage biotechnology company developing personalized, whole tumor-derived immunotherapies, today announced that an abstract reporting results from the Company’s randomized, multicenter, double-blind, placebo-controlled Phase 2b trial of IGV-001 in 99 patients with newly diagnosed glioblastoma (ndGBM) has been accepted for poster and rapid oral presentation...

WALTHAM, Mass. and BOULDER, Colo. — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM) and assigned a...